Lysosomal enzymes are synthesized in the endoplasmic reticulum (ER) and transferred to the Golgi complex by interaction with the Batten disease protein CLN8. Here we investigated the relationship of this pathway with CLN6, an ER-associated protein of unknown function that is defective in a different Batten disease subtype. Experiments focused on protein interaction and trafficking identified CLN6 as an obligate component of a CLN6-CLN8 complex (herein referred to as EGRESS: ER-to-Golgi relaying of enzymes of the lysosomal system) which recruits lysosomal enzymes at the ER to promote their Golgi transfer. Simultaneous deficiency of CLN6 and CLN8 did not aggravate mouse pathology compared to the single deficiencies, indicating that the EGRESS complex works as a functional unit. Mutagenesis experiments showed that the second luminal loop of CLN6 is required for the interaction of CLN6 with the enzymes but dispensable for interaction with CLN8, and in vitro and in vivo studies showed that CLN6 deficiency results in inefficient ER export of lysosomal enzymes and diminished levels of the enzymes at the lysosome. These results identify CLN6 and the EGRESS complex as key players in lysosome biogenesis and shed light on the molecular etiology of Batten disease caused by defects in CLN6.
INTRODUCTION
Lysosomes contain more than 50 soluble hydrolytic enzymes that mediate the degradation of macromolecules according to various catabolic programs. Lysosomal enzymes are synthesized at the endoplasmic reticulum (ER) and transferred to the endolysosomal system via the secretory route (1, 2) . Whereas the post-Golgi trafficking of lysosomal enzymes has been amply characterized (3), the early, pre-Golgi stages of lysosomal enzyme trafficking are only partially understood. We have recently reported that ER-to-Golgi transfer of newly synthesized lysosomal enzymes is mediated by the cargo receptor CLN8 (ceroid lipofuscinosis, neuronal, 8) (4). CLN8 is a ubiquitously expressed, multi-pass membrane protein that forms homodimers and localizes in the ER and the ER-Golgi intermediate compartment (5, 6) . CLN8 interacts with newly synthesized lysosomal enzymes in the ER, transfer them to the Golgi via COPII vesicles, and recycles back to the ER via COPI vesicles (4) . Absence of CLN8 results in inefficient ER exit and decreased levels of lysosomal enzymes in mouse tissues and patient-derived cells (4) , resulting in a subtype of Batten disease or neuronal ceroid lipofuscinosis (NCL) (7, 8) .
NCLs are a heterogeneous group of 13 genetically distinct progressive encephalopathies mainly presenting during infancy and childhood. The overall incidence of NCLs in the US is estimated to be 1:12,500 live births (9) . NCLs are classified as lysosomal storage disorders because a prominent feature emerging from the pathological analysis of patients' tissues is the intralysosomal accumulation of ceroid lipopigment (7) . A clear link between protein dysfunction and lysosomal pathology in NCLs is established by the observation that four NCL subtypes are caused by mutations in one of four lysosomal enzymes (PPT1, TPP1, CTSD, CTSF). In addition, at least four other NCL genes encode proteins that localize and presumably function in the lysosome (10) . Impaired trafficking of lysosomal enzymes due to CLN8 deficiency is another example linking impaired protein function to NCL molecular pathology (4) .
The ubiquitously expressed, multi-pass membrane protein CLN6 (ceroid lipofuscinosis, neuronal, 6; OMIM 601780) is the only other NCL protein that resides in the ER (11, 12) .
Remarkably, the clinical features of NCL patients with mutations in CLN6 or CLN8 are strikingly similar (13, 14) . Commonly associated symptoms include cognitive decline, seizures, retinopathy and gait difficulties with patients first reporting to the clinic between two and eight years of age (14) (15) (16) . Naturally occurring mouse models for CLN6 and CLN8 diseases have been widely characterized and have been shown to mimic many of the disease phenotypes (17) . Like human patients, mutant mice die prematurely and exhibit dysfunctional lysosomal metabolism in multiple tissues and organs (18, 19) . The underlying defective molecular pathway linking CLN6 deficiency to lysosomal dysfunction and NCL is unclear, as the molecular function of CLN6 is yet to be characterized (20) . Recent reports show alterations in metal homeostasis pathwaysmostly accumulation of zinc and manganese-and aberrant cell signaling related to Akt/GSK3 and ERK/MAPK pathways as characteristic features of CLN6 disease (21) . Impaired stability and function of the CLN6 interactor, collapsin response mediator protein-2 (CRMP-2), has also been associated with altered neurite maturation in CLN6 disease, possibly contributing to neuronal dysfunction and encephalopathy (22) . While these reports indicate associations between tissue pathology and disease symptoms, however, the function of CLN6 and its relationship with lysosomal pathways has remained elusive.
Based on the similarities between the clinical features associated with CLN6 and CLN8 deficiencies and the partially overlapping subcellular localization of the two proteins, we hypothesized that CLN6 also functions in ER-to-Golgi transfer of lysosomal enzymes. Here we investigated whether CLN6 acts as a cargo receptor for lysosomal enzymes and whether CLN6 function is redundant with, or dependent on, the function of CLN8. Our results show that CLN6 and CLN8 are obligate partners for the recruitment of newly synthesized lysosomal enzymes at the ER and that, differently from CLN8, CLN6 is not loaded into COPII vesicles but is retained in the ER, presumably to serve additional cycles of enzyme recruitment. We determine that the second luminal loop of CLN6 is required for the interaction of CLN6 with the enzymes and that CLN6 deficiency results in inefficient ER export of lysosomal enzymes and diminished levels of the enzymes at the lysosome. These results identify CLN6 as a key protein implicated in the biogenesis of lysosomes and shed light on the molecular etiology of Batten disease caused by defects in CLN6.
RESULTS

Loss of CLN6 does not aggravate pathology of CLN8-deficient mice.
To determine whether CLN6 and CLN8 have redundant functions we first conducted studies by using the Cln6 nclf and Cln8 mnd mouse lines (henceforth referred to as Cln6 -/and Cln8 -/-), which carry early frameshift mutations in Cln6 and Cln8 genes, respectively, resulting in the complete absence of CLN6 and CLN8 proteins (11, 19, 23, 24) . Life span analysis showed that Cln6 -/and Cln8 -/mice had a slightly different survival rate: The median survival of Cln6 -/mice was 450 days, while the median survival of Cln8 -/mice was 302 days (log-rank test; z = 7.07, P < 0.001), in line with previous reports (18, 19, 23) . Double KO mice had a median survival of 290 days, which was indistinguishable from that of Cln8 -/mice (log-rank test; z = 2.24, p = 0.025) ( Figure 1A ). Thus, simultaneous deficiency of CLN6 and CLN8 does not accelerate disease progression compared to CLN8 single deficiency.
A notable phenotype described in most mouse models of Batten disease is retinal degeneration, which eventually leads to complete blindness (25, 26) . Both Cln6 -/and Cln8 -/mouse lines display early-onset loss of vision that can be quantified by electroretinogram (ERG) analysis (25, 27) . To compare the visual function of single and double KO mouse lines, we performed scotopic and photopic ERGs to assess the function of rods and cones, respectively. Scotopic ERG was performed by measuring a-wave (photoreceptor) and b-wave (inner retina) amplitudes. The results from both scotopic ( Figure 1 , B and C) and photopic ( Figure 1D ) ERGs showed that, while all mutants displayed significant differences compared to age-matched wildtype (WT) mice, there was no difference in the comparison of the single and double KO lines.
Together, life span and ERG analyses suggest that CLN6 and CLN8 do not have redundant functions. We therefore set up to investigate whether they work in the same biological processas partners of a protein complex or in sequential steps of a common pathway.
CLN6 deficiency results in the depletion of various lysosomal enzymes from the lysosomal compartment. We recently demonstrated that, in absence of CLN8, lysosomes have diminished levels of various soluble lysosomal enzymes (4). To investigate whether CLN6 deficiency also results in defective lysosomal composition, we isolated lysosome-enriched fractions from the livers of pre-symptomatic, 6-week-old Cln6 -/mice and age-matched WT mice using a discontinuous Nycodenz-sucrose gradient as described (28) . Immunoblot analysis for the lysosomal membrane protein LAMP1 confirmed lysosomal enrichment in the collected fractions and showed no obvious changes in LAMP1 signal between WT and Cln6 -/samples (Supplemental Figure 1A) . We confirmed lysosomal enrichment by performing enzyme assay for β-hexosaminidase, a lysosomal enzyme that is not affected by CLN8 deficiency (4) and that also did not show changes upon deficiency of CLN6 (Supplemental Figure 1B) . We then performed immunoblot analysis for a set of enzymes for which antibodies able to recognize the mouse proteins are available. The results showed a general reduction in enzyme levels in the lysosomal fraction from Cln6 -/mice ( Figure 2 , A and B). Consistent with these results, we observed a decrease in lysosomal enzyme activities using proteins extracted from the lysosome-enriched fraction of Cln6 -/mice ( Figure 2C ). Real-time qPCR using liver RNAs, however, showed slightly increased transcription of lysosomal enzymes in Cln6 -/mice compared to WT controls ( Figure 2D ). In addition, confocal microscopy analysis of mouse embryonic fibroblasts (MEFs) from WT and Cln6 -/mice showed decreased overlap of CTSD and PPT1 with the lysosomal marker LAMP1 in absence of CLN6, whereas no obvious changes in the overlap of these enzymes with the ER protein KDEL were found (Supplemental Figure 1C -F). Together, these results show an absence of major defects in the expression of lysosomal enzymes and indicate that the cause of the observed lysosomal enzyme depletion must be post-translational.
CLN6 interacts with CLN8 but does not traffic to the Golgi complex. We next investigated whether CLN6 interacts with CLN8 by using bimolecular fluorescence complementation (BiFC), an assay in which proteins are tagged with either the N-or the C-terminus of YFP (Y1 and Y2, respectively), and fluorescence is emitted by reconstituted YFP upon interaction of the two tagged proteins (29) . BiFC assays performed by co-transfecting either CLN6-Y1 with Y2-CLN8 or CLN6-Y2 with Y1-CLN8 showed interaction between CLN6 and CLN8 under either Y1/Y2 configuration in HeLa cells ( Figure 3A , Supplemental Figure 2A ) and mouse embryonic fibroblasts (Supplemental Figure 2B ). As a control, we verified that CLN6 does not interact with lipase maturation factor 1 (LMF1) ( Figure 3A) , an ER transmembrane protein that acts as a cargo receptor for lipoprotein lipase (30) . Co-staining with KDEL showed colocalization with the reconstituted fluorescence, indicating that CLN6 and CLN8 interact at the ER ( Figure 3B ;
Pearson correlation coefficient = 0.76 ± 0.08, n = 10 cells). Co-IP experiments using tagged proteins expressed in HEK293-T cells confirmed that CLN6 interacts with CLN8 (Supplemental Figure 2C ) but not with LMF1 (Supplemental Figure 2D ). In addition, we generated a cell line in which endogenous CLN8 is fused to a myc tag by using CRISPR-Cas9 genome editing. Co-IP experiments confirmed interaction of CLN6 with endogenous CLN8 ( Figure 3C ).
Additional confocal microscopy analyses showed that both CLN6 and CLN8 colocalize with Sec16L, a marker for ER exit sites (Supplemental Figure 2E ). To test whether CLN6 is loaded into COPII vesicles we performed an in vitro COPII vesicle budding assay. We incubated membranes from myc-CLN6-transfected HeLa cells with rat liver cytosol and nucleotides for 1 hr at 30°C. Newly formed vesicles were collected and blotted for CLN6 and CLN8. Three known COPII cargo proteins-APP, ERGIC-53 and Sec22-were used as positive controls (31, 32) , and Ribophorin I, an ER-resident protein excluded from COPII vesicles (33) , was used as a negative control. Unlike CLN8, APP, and ERGIC-53, which were detected in COPII vesicles, CLN6 was excluded from COPII vesicles, similar to Ribophorin I ( Figure 3D ). Addition of Sar1 H79G, a dominant negative mutant that inhibits COPII vesicle formation (31) , blocked the inclusion of APP, Sec22, ERGIC-53, and CLN8 into newly formed vesicles, demonstrating that the process is specifically dependent on COPII.
In agreement with CLN6 exclusion from COPII vesicles, mutation of a putative ER retention/retrieval signal ( 5 RRR mutated to AAA) (34) present in the cytosol-facing N-terminus of CLN6 did not change the subcellular localization of CLN6 ( Figure 3 , E and F), consistent with previous observations (20) . Because other unknown protein signals could mediate retrieval of CLN6 from the Golgi to the ER, we also inhibited Golgi-to-ER retrograde trafficking using 1,3cyclohexanebis(methylamine) (CBM), a chemical inhibitor of COPI-mediated vesicular transport (35) . CBM treatment resulted in a change of CLN8 localization to the Golgi (Supplemental CLN8 trafficking to the Golgi is uncoupled from CLN6-CLN8 interaction. We next investigated whether the subcellular localizations of CLN6 and CLN8 are mutually dependent. We first tested whether abolishing Golgi-to-ER retrieval of CLN8 affects the subcellular localization of CLN6.
To this end, we co-transfected myc-tagged CLN6 with either full-length Y2-CLN8 or the retrieval-deficient CLN8 mutant Y2-CLN8dK (4). Confocal microscopy showed that, in either case, CLN6 localized at the ER in HEK293-T cells ( Figure 4 , A and B). To avoid interaction between CLN6 and endogenous CLN8, we repeated the test in a cell line in which CLN8 was knocked-out (CLN8 -/-) (4) and obtained a similar result (Supplemental Figure 2 , H and I). We then tested whether CLN8 can traffic to the Golgi independently of CLN6. To this aim, we generated CLN6 -/cells by CRISPR-Cas9 genome editing (Supplemental Figure 3 , A-C); as a control, we confirmed depletion of lysosomal enzymes in these cells, which could be rescued by CLN6 re-introduction (Supplemental Figure 3D ). Confocal microscopy showed that retrievaldeficient Y2-CLN8dK localizes to the Golgi in CLN6 -/cells ( Figure 4 , C and D), indicating that CLN8 trafficking is uncoupled from interaction with CLN6.
CLN6 interacts with lysosomal enzymes and the interaction requires CLN6's second luminal
loop. Next, we examined whether CLN6 interacts with the lysosomal enzymes. Coimmunoprecipitation assay using myc-tagged CLN6 and a set of YFP-tagged enzymes showed that CLN6 interacts with the precursor forms of enzymes that we previously characterized as CLN8 interactors (CTSD, PPT1, TPP1, and GALNS), while did not show interaction with HEXB, which also did not interact with CLN8 (4) ( Figure 5A ). Co-IP of CLN6 with the nonlysosomal secretory proteins AGN and TGF-1β resulted in the absence of any detectable interaction, thus supporting the notion that CLN6 interactions are specific. To gain insight into the domains of CLN6 involved in the interaction with the enzymes, we analyzed the structure and conservation of the CLN6 protein. CLN6 has a cytosolic N-terminus, seven transmembrane domains, and a C-terminus in the ER lumen (16, 20, 36) . The cytosolic and luminal loops connecting the transmembrane domains are all small (<15 amino acids), with the exception of the second luminal loop that is 48 amino-acid long ( Figure 5B ). Evolutionary constrained region analysis (37) using 26 vertebrate species showed that CLN6's second luminal loop (comprised between transmembrane domains 3 and 4) is the most constrained region of the protein (Supplemental Figure 4 ). We therefore hypothesized that this loop is involved in the interaction of CLN6 with the lysosomal enzymes. To test this hypothesis, we generated a CLN6 construct lacking the second luminal loop (CLN6ΔL2) by deleting the amino acids from position 135 to position 175 (Supplemental Figure 5 , A and B). We first verified that the CLN6ΔL2 protein, like full-length CLN6, localizes at the ER (Supplemental Figure 5C ). Given that CLN6 forms homodimers ( Figure 5C ) (20) , we also tested whether CLN6ΔL2 is able to dimerize with fulllength and ΔL2 CLN6 proteins. BiFC assays showed that full-length, YFP-tagged CLN6 forms a dimer (CLN6-Y1/CLN6-Y2) that is detectable by BiFC coupled with either confocal microscopy ( Figure 5D ) or flow cytometry (Supplemental Figure 5 , D and E). The CLN6-Y1/CLN6-Y2 dimer correctly localized in the ER as detected by confocal microscopy ( Figure 5E ). BiFC analysis showed that CLN6ΔL2 retains the ability to form dimers with full-length CLN6 (CLN6ΔL2-Y1/CLN6-Y2 and CLN6ΔL2-Y2/CLN6-Y1) as well as with itself (CLN6ΔL2-Y1/CLN6ΔL2-Y2) ( Figure 5F ). Thus, the second luminal loop of CLN6 is dispensable for protein stability and self-interaction. We then performed co-IP assay to test whether CLN6ΔL2 is able to interact with the lysosomal enzymes. Pull-down of myc-tagged CLN6ΔL2 followed by immunoblotting for Y1-tagged lysosomal enzymes (detectable with an anti-GFP antibody) showed that deletion of the second loop of CLN6 disrupts the interaction with the tested enzymes ( Figure 5G ). Thus, the second loop of CLN6 is required for the interaction of CLN6 with the lysosomal enzymes.
CLN6 and CLN8 are mutually necessary for their interaction with lysosomal enzymes. Next, we used CLN6 -/and CLN8 -/cells to investigate whether CLN6 and CLN8 are mutually necessary for their interaction with lysosomal enzymes. Co-IP assays showed that CLN6 is unable to interact with the lysosomal enzymes in CLN8 -/cells ( Figure 6A) ; similarly, the interaction of CLN8 with the lysosomal enzymes is abolished in CLN6 -/cells ( Figure 6B ). In the absence of CLN6, however, the ability of CLN8 to form homodimers was not abolished as seen by BiFC analysis followed by flow-cytometry ( Figure 6C ). Similarly, CLN6 was able to form homodimers in CLN8 -/cells ( Figure 6D ).
Based on these results, we conclude that CLN6 and CLN8 are obligate partners in the recruitment of newly synthesized lysosomal enzymes in the ER, and that the subsequent transfer of enzymes to the Golgi is mediated by CLN8 only. Although CLN6 is not loaded in COPII vesicles along with CLN8 and lysosomal enzymes, the observed decreased levels of enzymes in the lysosomal compartment upon CLN6 deficiency and the fact that CLN6 is essential for their recruitment in complex with CLN8 predict that, in absence of CLN6, ER-to-Golgi transfer of the enzymes may be inefficient. To test this hypothesis, we set out to monitor ER-to-Golgi trafficking of CTSD, PPT1 and GALNS by using the RUSH (Retention Using Selective Hooks) system (38) based on a recent report that showed that ER-to-Golgi transfer of CTSD occurs in a short time (< 30 min) and therefore requires a highly synchronized system for careful evaluation (39) . In the RUSH system, the test protein is fused with a KDEL-tagged streptavidin binding protein (SBP), which enables retention of the test protein in the subcellular compartment of choice by simultaneous expression of an organelle-targeted hook protein that contains a streptavidin domain. The interaction between the test protein and the hook protein is stable and can be reversed by the addition of biotin to outcompete SBP binding. Biotin supplementation thus results in a synchronous release of the test protein, which can be monitored for relocation by time-course confocal microscopy. For our experiments, we co-expressed an ER-targeted hook protein (38) with SBP-and GFP-fused CTSD, PPT1, and GALNS. We used SBP-, GFP-fused lysozyme C (LyzC) (39) as a control protein. We monitored the subcellular localization of CTSD, PPT1, GALNS, and LyzC at 0, 5, 10, and 20 minutes from their biotin-induced synchronous release in WT and CLN6 -/cells. As a quantitative measure, we assessed the overlap of the enzyme signal with that of the Golgi marker GM130 at each time point. The results showed that the absence of CLN6 caused a significant delay in ER-to-Golgi trafficking of the tested lysosomal enzymes, but not of LyzC (Figure 7 ), thus confirming that the lack of a functional CLN6-CLN8 complex for the recruitment of lysosomal enzymes results in their inefficient exit from the ER.
DISCUSSION
This study identifies CLN6 as a key factor for the biogenesis of lysosomes by uncovering its function as an obligate component of a CLN6-CLN8 complex that recruits lysosomal enzymes at the ER to promote their Golgi transfer. We refer to this complex as EGRESS (ER-to-Golgi relaying of enzymes of the lysosomal system) because of its role in recruiting lysosomal enzymes for Golgi delivery. The emerging model identifies a two-step process for the engagement of lysosomal enzymes in the ER and their transfer to the Golgi based on the cooperation between CLN6 and CLN8. In the first step, CLN6 and CLN8 form the EGRESS complex, which recruits the enzymes via an interaction that depends on both the large luminal loop of CLN6 (which is dispensable for the interaction with CLN8) and the large luminal loop of CLN8 (4). The absence of either protein makes the other unable to interact with the enzymes, indicating that the EGRESS complex is the minimal unit required for such interaction. In the second step, CLN8 is loaded into COPII vesicles to escort the enzymes to the cis-Golgi. It is possible that, during the loading into COPII vesicles, CLN6 is displaced by the interaction between CLN8 and COPII components, thus ending the loading cycle of the EGRESS complex.
Upon Golgi transfer, the enzymes are subsequently trafficked to the lysosomes via selective transport from the trans-Golgi network, whereas the empty receptor is recycled back to the ER.
If either component of the EGRESS complex is absent (or functionally defective), ER exit of the enzymes is inefficient, thereby resulting in enzyme depletion at the lysosome. A graphical depiction of inefficient enzyme exit from the ER upon CLN6 deficiency is reported in Figure 8 . ERp44 and MCFD2, respectively (40, 41) . In cells lacking functional ERGIC-53, its cargo proteins reach their destination at a slower rate and in reduced amounts (42, 43) . Similarly, exit of LyzC from the Golgi is delayed upon deletion of the LyzC sorting protein, Cab45 (39) .
Additional examples from recent studies include a variety of receptor systems and cargo proteins-Vti1a/b for Golgi export of Neuropeptide-Y (44), SURF4 for the secretion of PCSK9 (45) , and p24 for ER export of GPI-anchored proteins (46) . Bulk flow or lower-affinity binding to other cargo receptors can explain slower cargo transport (47) .
Recent studies focused on activation of TFEB, a master regulator of lysosomal biogenesis and function (48, 49) , indicate that lysosomal enhancement may counteract disease progression in animal models of lysosomal storage disorders, including a model of Batten disease (50, 51) .
Thus, the finding that defects in the EGRESS complex result in reduced amounts of enzymes at the lysosome identifies CLN6 and CLN8 diseases as candidate conditions for testing lysosomal enhancement therapy (52) . Interestingly, among the enzymes that are depleted upon CLN6 or CLN8 deficiency are TPP1 and CTSD, which are the defective proteins in two other NCL subtypes-CLN2 and CLN10, respectively (53) (54) (55) . Both TPP1 and CTSD are involved in the degradation of subunit c of mitochondrial ATP synthase (SCMAS) (56) (57) (58) , and studies that have characterized the composition of the storage material in various NCL subtypes have determined that SCMAS accumulates not only in CLN2 and CLN10 but also in CLN6 and CLN8 diseases (59) (60) (61) . Our results thus establish a framework to interpret the accumulation of SCMAS upon CLN6 and CLN8 deficiency as being caused by the depletion of the SCMAS degrading proteins, TPP1 and CTSD, at the lysosome. These observations also suggest therapeutic opportunities based on the possibility to provide the depleted enzymes exogenously via enzyme replacement therapy, an option that is being tested for several lysosomal enzymes including CLN2 but that is not available for transmembrane proteins such as CLN6 and CLN8 (62) (63) (64) (65) .
In summary, our findings address the molecular mechanism underlying Batten disease caused by loss of functional CLN6 and identify the EGRESS complex as the mediator of the recruitment of lysosomal enzymes in the ER for Golgi transfer. These findings uncover a previously unappreciated complexity of the early steps of lysosomal enzyme trafficking and shed light on the molecular pathogenesis of CLN6 disease, which can henceforth be interpreted as a disorder of impaired lysosomal biogenesis.
METHODS
Animal husbandry. Cln6 nclf mice on C57/BL6J background (Cln6 -/mice) were a gift from Dr. Susan Cotman (Harvard Medical School) and are available from the Jackson Laboratory (stock no: 003605). The Cln8 mnd mouse line (Cln8 -/line) was purchased from the Jackson Laboratory (stock no: 001612). Cln6 -/and Cln8 -/double KO mice were generated by crossing the single knock-out lines. Food and water were provided ad libitum. For subcellular fractionation and ERG experiments we used mice at 6 weeks of age. Only males were used for all analyses.
Investigators were blinded to mouse genotype during data acquisition, and no randomization was necessary. No data were excluded from this study. Table 1 lists the antibodies used throughout the study.
Molecular biology. Supplemental
Supplemental Table 2 lists the oligos used for cloning, genome editing, and PRC. CLN6 and CLN8 were cloned into myc and YFP vectors (backbone: pcDNA3.1 from Invitrogen) by retrotranscription of RNAs from HeLa and HEK293-T cells using the QuantiTect Reverse Transcription kit (Qiagen) followed by PCR-mediated amplification and plasmid insertion with the in-Fusion cloning kit (Clontech). The CLN6ΔL2 construct was obtained by removing the codons for amino acids 155-222 using the Q5 Site-Directed Mutagenesis kit (New England Biolabs).
Immunoblotting. Before harvesting, cells were rinsed in cold PBS and lysed using RIPA buffer 
Generation of CLN6 knock-out and CLN8 knock-in cells.
We used CRISPR-Cas9 genome editing to introduce a deletion in exon 2 of the CLN6 gene in HEK-293T cells. In brief, we designed two complementary oligonucleotide couples (Supplemental Table 2 ) using the online CRISPR design tool (http://crispr.mit.edu) coding for a guide RNA upstream of a protospacer adjacent motif (PAM) site in exon 2 of CLN6. The two oligos were annealed and subsequently cloned into the pX458 plasmid (66), followed by Sanger sequencing of the insert to confirm the correct sequence. HEK-293T cells were then transfected with 2 µg plasmid and split into a 96well plate by single-cell deposition. DNA was isolated from the expanded single colonies when confluent enough and used in PCRs using oligos to amplify exon 2 of CLN6 with CloneAmp HiFi PCR Premix (Clontech) according to the manufacturer's instructions; clones that were unable to produce an amplicon were subsequently Sanger sequenced, to confirm deletion of exon 2. We inserted a Myc tag (5'-GAACAAAAACTCATCTCAGAAGAGGATCTG-3') just before the stop codon of endogenous CLN8 in HEK-293T cells by combining CRISPR-Cas9 with single-stranded oligodeoxynucleotides (ssODNs) as described (67) . We selected recombinant clones by single colony expansion followed by gDNA extraction and PCR using oligos to amplify exon 3 of CLN8. Sanger sequencing confirmed the correct insertion of the Myc tag in a clone that was subsequently used for the described experiments. Beads with immunocomplexes were centrifuged at 3,000 × g and washed four times in lysis buffer with intermittent incubations, during each wash, for 6 min on the nutatotor at 4°C. After the fourth wash, beads were resuspended in Laemmli SDS sample buffer with β-Mercaptoethanol heated at 95°C for 10 min and then analyzed by immunoblotting. For experiments involving CLN8, samples were incubated at 37°C to avoid formation of CLN8 dimers and smears observed at higher temperatures which are hard to resolve on a SDS gel. Subcellular fractionation. Three mouse livers per sample were pooled and centrifuged in a discontinuous Nycodenz (Progen Biotechnik) density gradient as previously described (68), with modifications. Briefly, we homogenized tissues in an assay buffer (0.25 M sucrose, pH 7.2) and centrifuged at 4,800 × g for 5 min, and then at 17,000 × g for 10 min. The sediment of the second centrifugation was washed at 17,000 × g for 10 min. Consequently it was resuspended 1:1 vol/vol in 84.5% Nycodenz, and placed on the bottom of an Ultraclear (Beckman) tube. Above this, a discontinuous gradient of Nycodenz was constructed using the following percentages from bottom to top: 32.8%, 26.3%, and 19.8% Nycodenz. Samples were then centrifuged for 1 h in an SW 40 Ti rotor (Beckman) at 141,000 × g. Lysosome-enriched fractions were collected from the 26.3/19.8 interface and diluted in 5-10 volumes of assay buffer. Finally, they were centrifuged at 37,000 × g for 15 min. Pellets were then resuspended in 500 µl of assay buffer.
Enzyme assays. Enzyme activity assays were conducted by using fluorophore analogues of enzymes substrates, as previously described: TPP1 (69); GAA (70); GBA (71); GLB1 (72); NAGLU (73) . CBM assay. HeLa cells were plated on coverslips, 24 hours before the experiment in 24-well plates in DMEM at 37°C in the presence of 5% CO 2 . Cells were transfected the next day with either myc-tagged CLN6 or myc-tagged CLN8. 24 hours after transfection the media was removed, cells were washed with PBS, and 1,3-Cyclohexanebis(methylamine) (CBM) was added to each well at a final concentration of 2 mM for a 90 min period were indicated.
In vitro COPII vesicle budding reaction. Rat liver cytosol was prepared from fresh livers as previously described (31) . HeLa cells were co-transfected with CLN6-myc and CLN8-myc, permeabilized as previously described (74) , and used as donor membranes. Vesicle formation and purification was performed as described previously (74) . In brief, donor membranes were incubated where indicated with rat liver cytosol (4 mg/ml), ATP regeneration system, 0.3 mM GTP, and Sar1A H79G (10 ng/µl) in a final volume of 100 µl. The reaction was carried out at 30°C for 1 h and terminated by incubation on ice for 5 min. Donor membranes were removed by centrifugation at 14,000 × g for 12 min at 4°C. The resulting supernatant was centrifuged at 115,000 × g for 25 min at 4°C to collect COPII vesicles. Vesicle pellets were then resuspended Local evolutionary rates of CLN6 protein sequence were calculated using the webtool Aminode (www.aminode.org) (37) by feeding the indicated sequences as inputs for the custom analysis. Confocal microscopy analysis of WT and CLN6 -/-HEK293-T cells transfected with plasmids expressing enzymes fused with streptavidin binding protein (SBP)-eGFP (SBP-eGFP-CTSD, SBP-eGFP-GALNS, SBP-eGFP-PPT1) and streptavidin-KDEL ''anchor'' that retains SBP-containing proteins in the ER. Shown are representative images of cells without addition of biotin (0 min) and at 5, 10, and 20 min from the addition of biotin. Lysozyme C (LysC-SBP-eGFP), a secretory protein that does not reside in the lysosome, is used as a negative control. Manders' overlap coefficients measuring the degree of colocalization between the test protein (green signal) and the Golgi marker GM130 (red signal) are reported. Data are means ± SD (n > 20; *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant). Scale bars: 100 µm. 
